BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, October 8th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $92.31, for a total value of $2,492,370.00.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total transaction of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $4.90 during midday trading on Friday, hitting $96.96. 1,288,649 shares of the company’s stock traded hands, compared to its average volume of 1,088,842. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market capitalization of $24.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The firm has a fifty day moving average of $99.04 and a 200 day moving average of $95.16.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the previous year, the business posted ($1.60) EPS. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. On average, analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new stake in BioNTech in the 2nd quarter worth approximately $207,142,000. Bank of America Corp DE boosted its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of BioNTech during the 2nd quarter valued at about $39,385,000. Finally, SEB Asset Management AB acquired a new stake in shares of BioNTech during the 1st quarter valued at about $17,804,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. Finally, Morgan Stanley cut their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.69.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.